

ONE HUNDRED THIRTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**  
COMMITTEE ON ENERGY AND COMMERCE  
2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115  
Majority (202) 225-2927  
Minority (202) 225-3641

July 29, 2014

Dr. Robert J. Meyer  
Associate Professor  
Public Health Sciences  
University of Virginia  
P.O. Box 800717  
Charlottesville, VA 22908

Dear Dr. Meyer:


Thank you for appearing before the Subcommittee on Health on Wednesday, July 9, 2014, to testify at the hearing entitled "21st Century Cures: Modernizing Clinical Trials."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Tuesday, August 12, 2014. Your responses should be mailed to Sydne Harwick, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, D.C. 20515 and e-mailed in Word format to [Sydne.Harwick@mail.house.gov](mailto:Sydne.Harwick@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,

  
Joseph R. Pitts  
Chairman  
Subcommittee on Health

cc: The Honorable Frank Pallone, Jr., Ranking Member, Subcommittee on Health

Attachment

**Attachment—Additional Questions for the Record**

**The Honorable Tim Murphy**

1. You state that the development of psychiatric drugs is an area of great medical need that has experienced problems in dealing with poor neuroscientific targets for new drugs and specialized difficulties in successfully completing clinical trials for psychiatric drugs, which often times fail even when drugs are effective due to the nature of mental illness. Please expand upon these remarks pertaining to the problems psychiatric drug developers face and comment on any potential changes that could be made to resolve this problem.